Indication
Relapsed Solid Tumor
2 clinical trials
3 products
3 drugs
Product
CemiplimabClinical trial
A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade GliomaStatus: Terminated, Estimated PCD: 2023-05-10
Clinical trial
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)Status: Active (not recruiting), Estimated PCD: 2028-05-01
Product
AbemaciclibDrug
FOLFOXIRIProduct
TMZDrug
DinutuximabDrug
sargramostim